RapidAI is a global leader in AI and workflow technology to combat life-threatening neurovascular, cardiac, and vascular conditions. Its Rapid® platform powers clinical decision support and has analyzed over 10 million scans while appearing in 300+ peer-reviewed publications. Rapid NCCT Stroke is the first and only FDA-cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from non-contrast CT imaging; the company also has FDA-cleared modules for cerebral aneurysm management and suspected central pulmonary embolism. The platform is deployed in over 2,200 hospitals across 100+ countries and is being leveraged in more than 25 clinical trials. RapidAI is developing additional modules to expand into other disease states and to increase care-team efficiency and clinical decision making. The company announced a $75 million growth investment to drive platform innovation, add disease-state support, and accelerate go-to-market expansion into new regions and product verticals. RapidAI offers an end-to-end Rapid® platform that uses artificial intelligence to generate advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion/perfusion scans for stroke care. Its product suite includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid MRI and the SurgicalPreview® aneurysm management platform. The company reports its technology is based on intelligence from more than 1,000,000 scans across over 1,600 hospitals in more than 50 countries. RapidAI has expanded its clinical scope from ischemic stroke to hemorrhagic stroke and, after acquiring EndoVantage, now addresses aneurysm care. Management says the company has achieved sustained growth and uninterrupted profitability since going to market. The new funding is intended to accelerate global strategic growth and continued advancement of the Rapid platform and clinical products.

Total raised

$100M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2023